OptimizeRx (OPRX) Expected to Post Earnings on Thursday

OptimizeRx (NASDAQ:OPRX) is expected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $20.2040 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.13. The company had revenue of $19.84 million for the quarter, compared to the consensus estimate of $18.74 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. On average, analysts expect OptimizeRx to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

OptimizeRx Price Performance

OPRX opened at $6.37 on Thursday. The stock has a fifty day moving average of $5.63 and a 200-day moving average of $7.15. The firm has a market capitalization of $119.50 million, a P/E ratio of 18.20 and a beta of 1.08. OptimizeRx has a 12-month low of $4.54 and a 12-month high of $22.25. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16.

Hedge Funds Weigh In On OptimizeRx

Several institutional investors and hedge funds have recently modified their holdings of OPRX. Millennium Management LLC acquired a new position in shares of OptimizeRx in the fourth quarter worth $535,000. Inspire Investing LLC acquired a new stake in OptimizeRx during the fourth quarter valued at $1,175,000. Engineers Gate Manager LP acquired a new stake in OptimizeRx during the fourth quarter valued at $228,000. Boothbay Fund Management LLC grew its stake in OptimizeRx by 53.1% in the fourth quarter. Boothbay Fund Management LLC now owns 73,488 shares of the company’s stock valued at $901,000 after purchasing an additional 25,502 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its stake in OptimizeRx by 16.9% in the fourth quarter. Bridgeway Capital Management LLC now owns 69,029 shares of the company’s stock valued at $846,000 after purchasing an additional 10,000 shares in the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on OPRX shares. UBS Group set a $10.00 price target on OptimizeRx in a research report on Wednesday, May 13th. Stephens decreased their price objective on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 13th. B. Riley Financial decreased their price objective on OptimizeRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Wall Street Zen cut OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Finally, Lake Street Capital dropped their target price on OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.43.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.